Market Research Industry Reports

COPD [2017]: Bulletin #1

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS



Gain new key opinion leader (KOL) insights on the latest events happening in COPD.

Topics covered include expert opinions on Sunovions SUN-101 (glycopyrrolate), delivered via PARIs investigational eFlow nebuliser system. The KOLs also imparted their expectations for the US launch of a generic version of GlaxoSmithKlines Advair Diskus following the acceptance of Sandozs Abbreviated New Drug Application (ANDA) for its fluticasone propionate/salmeterol combination product. Finally, the experts shared their views on the updated National Institute for Health and Care Excellence (NICE) recommendations for AstraZenecas oral phosphodiesterase type 4 (PDE4) inhibitor Daxas (roflumilast).





Business Questions:

What are the KOLs opinions on SUN-101/eFlows delivery system?
How do experts anticipate SUN-101/eFlow will be differentiated from marketed longacting muscarinic antagonist (LAMAs)?
In which patients do KOLs anticipate SUN-101/eFlow will be most frequently prescribed?
What are KOL expectations for generic versions of GSKs Advair?
What impact will the launch of generic versions of Advair have on prescribing of originator products?
Do the experts have any reservations about prescribing generic versions of Advair?
How do experts view the updated NICE recommendations for roflumilast?
What impact will the updated NICE recommendations have on prescribing of roflumilast?
What concerns do the experts have regarding the use of roflumilast?

Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight [2018]

Established brands, generics, biologics and new MOAs fight for supremacy in the COPD treatment landscape Established treatments are coming under pressure from generics, new combinations, biologics and new MOAs as

USD 8495View Report

COPD: KOL Insight

Established brands, generics, biologics and new MOAs fight for supremacy in the COPD treatment landscapeEstablished treatments are coming under pressure from generics, new combinations, biologics and new MOAs as the

USD 8495View Report

RCC [2017]: Bulletin #2

This edition presents key opinion leader (KOL) views on recent developments in the renal cell carcinoma (RCC) market. Topics covered include; the early halting of the CheckMate-214 trial and subsequent

USD 1095View Report

RCC [2017]: Bulletin #1

This edition presents key opinion leader (KOL) views on recent developments in the renal cell carcinoma (RCC) market. Topics covered include; data released from Bristol-Myers Squibbs Phase III CheckMate-214 study,

USD 1045View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 1045
  • Enterprise Wide Licence    USD 2575
$ 1045

Reports Details

Published Date : Jul 2017
Country :Global
Category :Healthcare
Publisher :FirstWord Dossier
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube